<DOC>
	<DOC>NCT02275156</DOC>
	<brief_summary>The primary objective of this study was to evaluate the pharmacokinetics of evolocumab after a single 140 mg subcutaneous (SC) dose in adults with normal renal function or severe renal impairment or end-stage renal disease (ESRD) receiving hemodialysis.</brief_summary>
	<brief_title>Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Body mass index (BMI) of ≥ 18 and ≤ 35 kg/m² at screening. Subjects will have lowdensity lipoprotein cholesterol (LDLC) of 70190 mg/dL (inclusive) and on statin therapy. Other inclusion criteria may apply. Subject with current or prior history of statin intolerance Subject has previously received Evolocumab (AMG 145) or any other investigational therapy directed against PCSK9 Known substance abuse (eg, alcohol, licit or illicit drugs) within 12 months of day 1 Testing positive for alcohol and/or drugsofabuse at screening, day 1, or day 1 (alcohol only) History of hypersensitivity or allergic reaction to mammalianderived drug preparations Known sensitivity to any of the active substances or their excipients to be administered during dosing, eg, carboxymethylcellulose Other exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Subjects with normal renal function or severe renal impairment (RI) or end stage renal disease (ESRD) receiving hemodialysis</keyword>
</DOC>